Autres langues Rocket Pharmaceuticals, Inc.

Actions

RCKT

US77313F1066

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 03/05/2024			Varia. 5j.	Varia. 1 janv.
23,47 ^USD	+3,07%		+6,20%	-21,69%

16/04	Un initié de Rocket Pharmaceuticals a vendu des actions pour une valeur de 1 945 785 $, selon un récent dépôt auprès de la SEC	MT
11/04	Un initié de Rocket Pharmaceuticals a vendu des actions pour une valeur de 308 763 $, selon un récent dépôt auprès de la SEC	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Rocket Pharmaceuticals Insider Sold Shares Worth $1,945,785, According to a Recent SEC Filing	16/04
Rocket Pharmaceuticals Insider Sold Shares Worth $308,763, According to a Recent SEC Filing	11/04
Rocket Pharmaceuticals Says European Medicines Agency Accepted Marketing Authorization Application for RP-L102	02/04
Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia	02/04
Rocket Pharmaceuticals, Inc. Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia	02/04
Rocket Pharmaceuticals Appoints Aaron Ondrey as CFO	26/03
Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team	26/03
Rocket Pharmaceuticals, Inc. Announces Appointment of Aaron Ondrey as Chief Financial Officer	26/03
Rocket Pharmaceuticals, Inc. Announces Executive Appointments	26/03
Thinking about buying stock in Ocean Biomedical, CASI Pharmaceuticals, Cardiol Therapeutics, Geron, or Rocket Pharmaceuticals?	05/03
Rocket Pharmaceuticals Q4 Loss Narrows	26/02
Rocket Pharmaceuticals: Q4 Earnings Snapshot	26/02
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress	26/02
Rocket Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	26/02
North American Morning Briefing : S&P 500 Futures -2-	23/02
Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI for the Treatment of Severe Leukocyte Adhesion Deficiency-I	14/02
Rocket Pharmaceuticals Says FDA Extends Review Timeline for Kresladi; Shares Decline	13/02
FDA Extends Review of Rocket Pharma's Proposed Kresladi	13/02
Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI™ (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)	13/02
Rocket Pharmaceuticals, Inc. Announces Update on Fda Review Timeline of Kresladi? (Marnetegragene Autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (Lad-I)	13/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Rocket Pharmaceuticals, Inc.

Actions

RCKT

US77313F1066

Autres langues

Filtres